307B

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a 52-week, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to 12 years \< Tanner Stage 3) and adolescents (\> 12 years old or \> Tanner Stage 3 to 16 years old) of both genders. Because response to some therapies in adult hypertension appears to be different in black and non-black populations, the recruitment will have a mixture of black and non-black subjects. Pharmacokinetic measurements were performed on a subset of patients. Thirty subjects (15 subjects each in the 6 to 12 year age group and the 13 to 16 year age group) had a series of blood samples drawn. All subjects had a trough plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18) with the exception of those subjects who completed Protocol 307B (16 week open-label treatment).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metoprolol in Acute Myocardial Infarction. A PK/PD Study

NCT01523054

Acute Myocardial Infarction

COMPLETED PHASE1

Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.

NCT01311700

Myocardial Infarction

COMPLETED PHASE4

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

NCT01213173

Angina Pectoris

COMPLETED PHASE4

The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents

NCT00475462

Syncope, Vasovagal

COMPLETED NA

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

NCT01970059

Hypertension

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

metoprolol succinate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female between the ages of 6 and 16 years inclusive at the time of screening.
* Have a negative urine pregnancy test, if female of childbearing potential. Have a signed informed consent by a parent or a legal guardian and an assent form signed by the subject (if applicable).
* Have hypertension that is either:

1. Have successfully completed Protocol 307A, or, or
2. Have dropped out of Protocol 307A or failed screening for Protocol 307A for sitting SBP/DBP greater than 20/10 mm Hg over the 95 th percentile using height adjusted charts for age and gender (see Appendices B through E inclusive), or
3. Have not enrolled in Protocol 307A but meet all screening criteria for Protocol 307B and are enrolled at sites that have already randomized 6 subjects into Protocol 307A.
* Have the ability to swallow tablets.

Exclusion Criteria

* Have secondary hypertension due to coarctation of aorta, pheochromocytoma, hyperthyroidism or Cushing's syndrome.
* Have a heart rate \< 55 beats per minute at Visit 1.
* Have a history of asthma and/or recurring pulmonary disease or infections.
* Have a history of cystic fibrosis.
* Have a known hypersensitivity reaction to beta-blockers.
* Have a known bleeding, coagulation or platelet disorder that can interfere with blood sampling.
* Have a history of Insulin Dependent Diabetes Mellitus.
* Be in any situation or have any condition which, in the opinion of the investigator or sponsor, may interfere with participation in the study or produce a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints.
* Have received any investigational agent for any therapeutic reason within 30 days prior to receiving study medication.
* Have a clinically significant cardiac valvular disease.
* Have a diagnosis of heart failure.
* Have clinically significant arrhythmia. This is defined as any arrhythmia requiring medical therapy or that causes symptoms.
* Atrioventricular (AV) conduction disturbance, ie, second or third degree AV block.
* Be unable or unwilling to comply with the study requirements.
* Be non-compliant during the single-blind placebo run-in period of the study as defined by missing three or more doses between study visits.
* Have impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than one and one half times the upper limit of the normal range for AST or ALT.
* Have a known history of bilateral renal artery stenosis, or unilateral renal artery stenosis to a single kidney. Nephrotic subjects who are not in remission should be excluded.
* Be pregnant or breast-feeding an infant.
* Currently taking medications known to inhibit CYP2D6, such as quinidine, fluoxetine, paroxetine and propafenone.
* Currently taking catecholamine-depleting medications such as reserpine. For any subject who is currently taking medications known to inhibit CYP2D6 or any catecholamine-depleting medication, the sponsor must be contacted to assess feasibility for inclusion into the study.
* Currently taking any selective serotonin re-uptake inhibitors (SSRIs) or atypical antipsychotic medication.
* Have a history of alcohol or drug abuse, or have a positive urine screen for drugs of abuse or alcohol.

Minimum Eligible Age

6 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No